Posted by Michael Wonder on 11 Oct 2016
ICER releases corrected evidence report on treatments for non-small-cell lung cancer
7 October 2016 - PD-1 value-based price benchmarks are updated while the main conclusions of the analysis remain unchanged.
The ICER has released a corrected version of its evidence report assessing the comparative clinical effectiveness and value of treatments for non-small-cell lung cancer (NSCLC).
This updated version corrects an error in the calculation of the discounts from list price for PD-1 and PD-L1 drugs to reach the ICER value-based price benchmarks associated with long-term cost-effectiveness. Discount figures for TKI drugs for NSCLC were calculated correctly and require no update. The conclusions of the analysis remain unchanged: significant discounts from list price for PD-1 and PD-L1 drugs would be needed to reach a price range that aligns well with how much added benefit these drugs provide for patients.
